Isoniazid-induced hepatotoxicity in patients with latent tuberculosis – experience from a tuberculosis center

Q3 Medicine

Indian Journal of Tuberculosis Pub Date : 2025-04-01 DOI:10.1016/j.ijtb.2023.12.010

Bruno S. Silva , Beatriz Ferraz , Nuno Faria , Maria Inês Costa , Ricardo Reis

{"title":"Isoniazid-induced hepatotoxicity in patients with latent tuberculosis – experience from a tuberculosis center","authors":"Bruno S. Silva , Beatriz Ferraz , Nuno Faria , Maria Inês Costa , Ricardo Reis","doi":"10.1016/j.ijtb.2023.12.010","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><span>Although the prevalence of isoniazid-induced hepatotoxicity (IIH) has been documented in patients with tuberculosis, its prevalence in latent </span>tuberculosis infection<span> (LTBI) patients is less studied. The aim of this study was to investigate the prevalence of IIH in a group of LTBI patients who received isoniazid monotherapy.</span></div></div><div><h3>Methods</h3><div><span>Retrospective cohort study<span> including patients who underwent isoniazid monotherapy for LTBI in an outpatient clinic between January 1st</span></span><sup>,</sup> 2020, and June 30th<sup>,</sup> 2021.</div></div><div><h3>Results</h3><div><span><span>A total of 274 cases were analyzed. About half (50.4 %) were male; median age was 53 years-old (minimum: six; maximum 89). The most common comorbidities were dyslipidemia (25.5 %), </span>body mass index between 25 and 30 kg/m</span><sup>2</sup><span><span> (20.4 %), obesity (14.7 %) and chronic hepatic disease (CHD; 12.8 %). 47.4 % had systemic inflammatory diseases<span><span>. Significant elevation of liver enzymes was documented in 27 % of patients. IIH was documented in 20.4 % of patients; there was a statistically significant relation with </span>dyslipidemia (p < 0.001), CHD (p = 0.023), </span></span>psoriasis<span> (p = 0.025), spondyloarthropathies (p = 0.017) and male sex (p = 0.042). Dyslipidemia showed a strong correlation to IIH (adjusted odds ratio: 8.045).</span></span></div></div><div><h3>Conclusion</h3><div>Patients with dyslipidemia had an adjusted odds ratio of 8.045 to develop IIH. Future multicentric studies should be started to better explore this relation, as well as treatment options.</div></div>","PeriodicalId":39346,"journal":{"name":"Indian Journal of Tuberculosis","volume":"72 2","pages":"Pages 194-197"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Tuberculosis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0019570723002275","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Although the prevalence of isoniazid-induced hepatotoxicity (IIH) has been documented in patients with tuberculosis, its prevalence in latent tuberculosis infection (LTBI) patients is less studied. The aim of this study was to investigate the prevalence of IIH in a group of LTBI patients who received isoniazid monotherapy.

Methods

Retrospective cohort study including patients who underwent isoniazid monotherapy for LTBI in an outpatient clinic between January 1st^, 2020, and June 30th^, 2021.

Results

A total of 274 cases were analyzed. About half (50.4 %) were male; median age was 53 years-old (minimum: six; maximum 89). The most common comorbidities were dyslipidemia (25.5 %), body mass index between 25 and 30 kg/m² (20.4 %), obesity (14.7 %) and chronic hepatic disease (CHD; 12.8 %). 47.4 % had systemic inflammatory diseases. Significant elevation of liver enzymes was documented in 27 % of patients. IIH was documented in 20.4 % of patients; there was a statistically significant relation with dyslipidemia (p < 0.001), CHD (p = 0.023), psoriasis (p = 0.025), spondyloarthropathies (p = 0.017) and male sex (p = 0.042). Dyslipidemia showed a strong correlation to IIH (adjusted odds ratio: 8.045).

Conclusion

Patients with dyslipidemia had an adjusted odds ratio of 8.045 to develop IIH. Future multicentric studies should be started to better explore this relation, as well as treatment options.

查看原文本刊更多论文

潜伏肺结核患者异烟肼所致肝中毒--来自结核病中心的经验

背景：虽然异烟肼引起的肝毒性（IIH）在结核病患者中的患病率已被证实，但其在潜伏性结核感染（LTBI）患者中的患病率研究较少。本研究的目的是调查一组接受异烟肼单药治疗的LTBI患者中IIH的患病率。方法：回顾性队列研究，纳入2020年1月1日至2021年6月30日在门诊接受异烟肼单药治疗LTBI的患者。结果共分析274例。约一半（50.4%）为男性；年龄中位数为53岁(最低6岁；最大的89)。最常见的合并症是血脂异常（25.5%）、体重指数在25 - 30 kg/m2之间（20.4%）、肥胖（14.7%）和慢性肝病(冠心病；12.8%)。47.4%有全身性炎性疾病。27%的患者肝酶明显升高。20.4%的患者记录为IIH；与血脂异常有统计学意义(p <；0.001)、冠心病（p = 0.023）、牛皮癣（p = 0.025）、脊椎关节病（p = 0.017）和男性（p = 0.042）。血脂异常与IIH有很强的相关性（校正优势比：8.045）。结论血脂异常患者发生IIH的调整优势比为8.045。未来的多中心研究应该开始更好地探索这种关系，以及治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Tuberculosis Medicine-Infectious Diseases

CiteScore

2.80

自引率

0.00%

发文量

103

期刊介绍： Indian Journal of Tuberculosis (IJTB) is an international peer-reviewed journal devoted to the specialty of tuberculosis and lung diseases and is published quarterly. IJTB publishes research on clinical, epidemiological, public health and social aspects of tuberculosis. The journal accepts original research articles, viewpoints, review articles, success stories, interesting case series and case reports on patients suffering from pulmonary, extra-pulmonary tuberculosis as well as other respiratory diseases, Radiology Forum, Short Communications, Book Reviews, abstracts, letters to the editor, editorials on topics of current interest etc. The articles published in IJTB are a key source of information on research in tuberculosis. The journal is indexed in Medline